Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neda Kalhor

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Cancer Innovation|July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSahil Seth, Runzhe Chen, Yang Liu, et al.
Nature Cancer|February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancerC Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Cancer Research|May 25, 2016
Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing AirwayYasminka Jakubek, Wenhua Lang, Selina Vattathil, et al.
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2022
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironmentNeal Akhave, Jiexin Zhang, Erin Bayley, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Discovery|September 11, 2012
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers, Jing Wang, Monique B Nilsson, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Cancer Innovation|July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSahil Seth, Runzhe Chen, Yang Liu, et al.
Nature Cancer|February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancerC Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Cancer Research|May 25, 2016
Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing AirwayYasminka Jakubek, Wenhua Lang, Selina Vattathil, et al.
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2022
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironmentNeal Akhave, Jiexin Zhang, Erin Bayley, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Discovery|September 11, 2012
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers, Jing Wang, Monique B Nilsson, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Pageof 14